More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$318004414
EPS
-1.95
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
0.763147
Previous close
$4.12
Today's open
$4.11
Day's range
$3.85 - $4.18
52 week range
$2.92 - $6.45
show more
CEO
Jean-Pierre Sommadossi
Employees
55
Headquarters
Boston, MA
Exchange
Nasdaq Global Select
Shares outstanding
80304145
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Atea Pharmaceuticals: A Clean DDI Profile And Shorter Treatment Duration Threaten Current Market Leaders
Atea Pharmaceuticals is a Buy: positive Phase 3 HCV data and a runway into mid-2028 support a steep discount to estimated value. BEM/RZR achieved a 94% cure rate versus Epclusa's 95%, with an eight-week regimen and clean drug-interaction profile supporting differentiation. C-FORWARD data in early 2027 are the critical catalyst; success could support a mid-2027 NDA, while failure could derail submission and increase dilution.
Seeking Alpha • Nov 13, 2026

Atea Pharmaceuticals, Inc. (AVIR) Q3 2026 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (AVIR) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 10, 2026

What Atea Pharmaceuticals (AVIR) Said on Its Q3 Earnings Call
Atea Pharmaceuticals NASDAQ: AVIR is targeting a mid-2027 U.S. application for its hepatitis C treatment, pending results from a second late-stage trial, and has secured a credit facility of up to $200 million to support its development and commercial plans.
MarketBeat • Nov 10, 2026

Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection
GlobeNewsWire • Nov 9, 2026

Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital
BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it has entered into a credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $200 million. The facility strengthens Atea's financial position and provides strategic and operational flexibility as the Company expands its commercial-related activities in anticipation of the product launch of the regimen of bemnifosbuvir/ruzasvir (BEM/RZR) in the United States (US) for the treatment of chronic hepatitis C virus (HCV), if approved, and advances the Company's clinical program for hepatitis E virus (HEV).
GlobeNewsWire • Nov 9, 2026

Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Monday, November 9, 2026, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2026, and to provide a business update.
GlobeNewsWire • Nov 2, 2026

Atea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Atea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha • Sep 15, 2026

Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026 at 12:20 p.m.
GlobeNewsWire • Sep 8, 2026

Atea Pharmaceuticals Q2 Earnings Call Highlights
Atea Pharmaceuticals NASDAQ: AVIR reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and secondary endpoints against the standard-of-care regimen sofosbuvir/velpatasvir, marketed as Epclusa.
MarketBeat • Aug 12, 2026

Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 13, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Atea Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.